Table 3:
Comparison of HIV-1 TNA Concentration in BLD and DBS Specimens
| TYPE | HIV-1 TNA copies Dl1 | D10 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n= | Geometric Mean | MIN | MAX | n= | Geometric Mean | MIN | MAX | p-value | |
| BLD | 36 | 3,128 | 303 | 15,972 | 36 | 2,660 | 216 | 16,777 | 0.392 |
| DBS | 36 | 994 | 57 | 9,057 | ND | ND | ND | ND | <0.0013 |
The geometric mean, miminum (MIN), and maximum (MAX) HIV-1 TNA concentration in 36 samples tested at day 1 (frozen whole blood [BLD], dried blood spots [DBS]) and day 10 (BLD) after collection. HIV-1 TNA concentration was measured using a modified Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 RNA assay (section 3.4).
BLD HIV-1 TNA copies/0.1mL created on the same day of collection (D1) vs. BLD HIV-1 TNA copies/0.1 mL from samples created after ten days of storage (D10); p-value derived from mixed model using day as fixed factor and panel as random factor (interaction of day * panel, p = 0.95); note fold change from Day 1 to Day 10 in BLD= 0.85.
BLD HIV-1 TNA copies/0.1 mL for D1 testing vs. DBS HIV-1 TNA copies/spot (0.075 mL) from D1 testing; p-value derived from mixed model using sample type as fixed factor and panel as random factor (interaction of sample type * panel, p = 0.14); note fold difference between DBS vs BLD is 0.32.